Compare Enact Holdings Inc (ACT) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Enact Holdings Inc trades at $45.26 (market cap $6.35B), while Amphastar Pharmaceuticals Inc trades at $18.8 (market cap $885.83M). The key difference: Enact Holdings Inc is far larger — about 7.2× Amphastar Pharmaceuticals Inc's market cap, and Enact Holdings Inc pays a 1.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACT | AMPH | |
|---|---|---|
Market Cap | $6.35B | $885.83M |
Sector | Technology | Health |
52-Week High | $45.71 | $30.81 |
52-Week Low | $34.39 | $16.87 |
Enterprise Value | $6.55B | $1.28B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.
The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
